Discovery and development of SV2A PET tracers: Potential for imaging synaptic density and clinical applications

Joel Mercier; Laurent Provins; Anne Valade

doi:10.1016/j.ddtec.2017.11.003

Discovery and development of SV2A PET tracers: Potential for imaging synaptic density and clinical applications

Drug Discov Today Technol. 2017 Nov:25:45-52. doi: 10.1016/j.ddtec.2017.11.003. Epub 2017 Dec 1.

Authors

Joel Mercier¹, Laurent Provins², Anne Valade²

Affiliations

¹ UCB Pharma, Braine l'Alleud, Belgium. Electronic address: Joel.mercier@ucb.com.
² UCB Pharma, Braine l'Alleud, Belgium.

PMID: 29233267
DOI: 10.1016/j.ddtec.2017.11.003

Abstract

Imaging synaptic density in vivo has promise for numerous research and clinical applications in the diagnosis and treatment monitoring of neurodegenerative and psychiatric diseases. Recent developments in the field of PET, such as SV2A human imaging with the novel tracers UCB-A, UCB-H and UCB-J, may help in realizing this potential and bring significant benefit for the patients suffering from these diseases. This review provides an overview of the most recent progress in the field of SV2A PET imaging, its potential for use as a biomarker of synaptic density and the future development areas.

Publication types

Review

MeSH terms

Animals
Biomarkers / metabolism
Carbon Radioisotopes
Chemistry, Pharmaceutical
Fluorine Radioisotopes
Humans
Membrane Glycoproteins / metabolism*
Nerve Tissue Proteins / metabolism*
Positron-Emission Tomography / methods*
Pyridines
Pyrrolidinones
Radioactive Tracers
Synapses / metabolism*

Substances

Biomarkers
Carbon Radioisotopes
Fluorine Radioisotopes
Membrane Glycoproteins
Nerve Tissue Proteins
Pyridines
Pyrrolidinones
Radioactive Tracers
UCB-H compound
SV2A protein, human